Metabolic surgery

Metabolic surgery is now one of the most effective therapeutic strategies for treating type 2 diabetes mellitus associated with obesity, because it acts not only through mechanical restriction of food intake or weight loss, but also profoundly modifies the patient’s endocrine, enteroinsular, and metabolic milieu. The term has progressively accompanied and partly superseded bariatric surgery when the clinical objective is described not merely as weight reduction, but as improvement of associated metabolic diseases, particularly hyperglycemia, insulin resistance, metabolic dysfunction-associated steatotic liver disease, hypertension, dyslipidemia, and obstructive sleep apnea. In type 2 diabetes mellitus, this approach has a very strong biological basis because many procedures modify intestinal transit, incretin secretion, hepatic and peripheral insulin sensitivity, hunger, food preference, and the dynamics of energy balance.

In recent years, metabolic surgery has moved beyond a residual role reserved only for extremely severe obesity and has become firmly established in treatment algorithms for type 2 diabetes, particularly when the patient has clinically significant obesity, inadequate metabolic control despite well-conducted medical therapy, a high medication burden, progression of comorbidities, or a need for a more decisive intervention on body weight. This does not mean that surgery is a shortcut or a universal solution. On the contrary, it requires rigorous selection, multidisciplinary assessment, nutritional and psychological preparation, precise knowledge of the available techniques, and long-term follow-up. Its efficacy can be extraordinary, but benefits are greatest when the procedure is embedded in a well-structured care pathway and when the patient maintains long-term adherence to follow-up, supplementation, and the required behavioral changes.

Historically, these procedures were developed as interventions for reducing body weight, but clinical observation soon showed that in many patients with type 2 diabetes mellitus, glycemic improvement occurred even before weight loss became substantial. This finding changed the pathophysiologic interpretation of the operations. Weight loss remains a central mechanism, but it is not the only one. After some procedures, there is a rapid reduction in energy intake, altered absorption, increased secretion of intestinal hormones such as glucagon-like peptide 1, reduced drive to eat, and changes in bile acid metabolism, the microbiota, and entero-pancreatic signaling. Surgery therefore does not merely reduce gastric volume or the capacity to consume food, but remodels metabolic circuits that are profoundly impaired in diabetes.

This interpretation explains why the term metabolic surgery is particularly appropriate today in type 2 diabetes. In some patients, surgery allows a rapid reduction in blood glucose, insulin requirements, or oral therapy, together with improvements in insulin resistance, triglycerides, blood pressure, and hepatic steatosis. Its superiority over intensive medical therapy alone, documented in randomized trials and long-term cohorts, does not depend on a single mechanism but on the convergence of several effects: substantial weight loss, lower lipotoxic burden, improved residual beta-cell function, increased insulin sensitivity, and a marked reduction in medication requirements. Surgery should therefore not be viewed as an “extreme” alternative to diabetology, but as an extension of it in cases where the patient’s pathophysiology requires a higher-intensity intervention.

It should, however, be clarified that the metabolic significance of surgery is not identical across all procedures. Some techniques are predominantly restrictive, others are mixed, and others have a more pronounced malabsorptive component. Accordingly, not only the potency of weight loss and diabetes remission changes, but also the profile of complications, nutritional deficiencies, postprandial hypoglycemia, dumping syndrome, and monitoring requirements. Metabolic surgery is therefore a family of procedures with a common rationale, not a single undifferentiated technical act.

Contemporary indications are broader than in the past and reflect the increasing robustness of the evidence. In people with type 2 diabetes mellitus and severe obesity, metabolic surgery is now considered an established therapeutic option. The most recent guidelines from major scientific societies, including diabetes and surgical organizations, recommend surgery in patients with a high body mass index and suggest considering it at lower values when diabetes remains inadequately controlled or when weight loss and improvement of comorbidities are not achieved with well-conducted nonsurgical treatments.

In practical terms, modern criteria are no longer based solely on the old rigid scheme that limited surgery to patients with a body mass index of at least 40 kilograms per square meter, or at least 35 with comorbidities. Today, type 2 diabetes with obesity is assigned a specific priority. The presence of poorly controlled diabetes, a high medication burden, insulin use, progression of complications, significant hepatic steatosis, obstructive sleep apnea syndrome, or functional deterioration related to excess weight strengthens the rationale for surgery. In Asian populations, in whom metabolic risk emerges at lower body mass index values, thresholds are lower.

This broader indication should not, however, be trivialized. Metabolic surgery is not indicated solely because the patient wishes to lose weight or reduce medications. There must be genuine clinical consistency between the severity of metabolic disease, the likelihood of benefit, and the patient’s ability to sustain follow-up. Uncontrolled causes of secondary obesity, unstable psychiatric conditions, untreated active eating disorders, uncontrolled addictions, severe anesthetic contraindications, and situations in which adherence to postoperative monitoring is predictably absent should also be excluded. The correct decision therefore does not arise from a single number, but from integration of body mass index, diabetes history, residual beta-cell function, comorbidities, frailty, and expected adherence to the care pathway.

Factors supporting metabolic surgery

• Clinically significant obesity associated with type 2 diabetes mellitus
• Inadequate glycemic control despite well-conducted medical and nutritional therapy
• Need to reduce medication burden, body weight, and overall cardiometabolic risk
• Presence of obesity-related comorbidities such as hepatic steatosis, obstructive sleep apnea, hypertension, and dyslipidemia
• Patient willingness to undergo long-term nutritional, medical, and surgical follow-up

The preoperative phase is the true determinant of treatment quality. A properly selected patient is more likely to achieve diabetes remission, fewer complications, and good postoperative quality of life. Assessment should be multidisciplinary and include at least a surgeon, diabetologist or endocrinologist, dietitian, anesthesiologist, and, when indicated, a psychologist or psychiatrist, hepatologist, cardiologist, and pulmonologist. This is not an organizational formality. Each professional is needed to identify specific risks and determine whether the patient is genuinely ready to undergo surgery.

From a metabolic perspective, diabetes duration, glycated hemoglobin trends, current treatment, episodes of hypoglycemia, insulin requirements, the presence of microvascular and macrovascular complications, kidney function, lipid profile, blood pressure, liver status, and the presence of metabolic dysfunction-associated steatosis or steatohepatitis should be documented. This information is needed both to define the indication and to predict the likelihood of remission. In general, shorter diabetes duration, less insulin exposure, and better beta-cell reserve are associated with more favorable glycemic outcomes after surgery.

From a nutritional perspective, it is essential to identify deficiencies already present before surgery. Many patients with obesity are not nutritionally “protected,” but have deficiencies of vitamin D, iron, folate, or vitamin B12, or abnormalities of calcium–phosphate metabolism. Preoperative identification is crucial because surgical procedures, particularly those with a greater malabsorptive component, may worsen pre-existing deficiencies. For the same reason, eating behavior should be assessed, identifying binge eating, chaotic eating, alcohol misuse, or patterns incompatible with postoperative management.

Psychological assessment is not intended to label the patient as morally “suitable” or “unsuitable,” but to determine whether conditions are present that make a poor outcome more likely: untreated major depressive disorder, active eating disorders, limited understanding of the procedure, unrealistic expectations, poor social support, or substance dependence. Metabolic surgery requires sustained changes in habits, supplementation, and follow-up. If this dimension is neglected, even a technically flawless operation may produce clinically inferior results.

Among the most commonly used procedures are vertical gastrectomy, often referred to by the English term sleeve gastrectomy, and Roux-en-Y gastric bypass. Both are effective, but have different profiles. Sleeve gastrectomy substantially reduces gastric volume and removes most of the gastric fundus, reducing ghrelin secretion and producing rapid satiety. Roux-en-Y gastric bypass combines gastric restriction with diversion of digestive transit, producing a more pronounced effect on the incretin profile, absorption, and the postprandial glycemic response.

In selected centers and for particular indications, procedures such as one-anastomosis gastric bypass and more malabsorptive operations such as biliopancreatic diversion with duodenal switch or its variants are also used. These techniques may provide very high metabolic potency, but at the cost of a greater risk of nutritional deficiencies, diarrhea, protein malabsorption, or complications related to intestinal rearrangement. Their indication therefore requires an experienced center and careful patient selection.

The choice of operation is never neutral. In a patient with significant gastroesophageal reflux, for example, sleeve gastrectomy may not be the most favorable choice. In a patient with long-standing diabetes, severe obesity, and a need for a more intensive metabolic effect, gastric bypass may be more attractive. This greater potency, however, must be balanced against the risk of dumping, postprandial hypoglycemia, nutritional deficiencies, and internal complications. In other words, there is no ideal technique in the abstract. There is a procedure most consistent with the individual patient’s clinical profile, anatomy, comorbidities, operative risk, and ability to adhere to long-term follow-up.

Metabolic surgery is now one of the most effective interventions for achieving substantial and durable weight loss in people with obesity and type 2 diabetes. Recent guidelines emphasize that mean weight loss often exceeds 20% of initial body weight, with a much greater impact than most nonsurgical therapies. In the context of diabetes, this translates into a marked reduction in insulin resistance, lower glycated hemoglobin, reduced medication requirements, and, in a substantial proportion of selected patients, achievement of remission.

Improvement in diabetes depends on several factors. The reduction in caloric intake and liver fat is very rapid, as is the decrease in hepatic glucose production. Subsequently, overall weight loss, reduction of visceral fat, improvement in muscle insulin sensitivity, and remodeling of intestinal hormone secretion come into play. Long-term randomized and observational studies have shown that, compared with intensive medical therapy, surgery more often achieves stringent glycemic targets, greater medication discontinuation, and higher rates of diabetes remission.

Efficacy is not limited to glycemia. After metabolic surgery, hypertension, dyslipidemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, joint pain, and quality of life often improve. This broader benefit is essential because a patient with diabetes almost never has hyperglycemia alone, but an entire constellation of complications driven by excess adiposity. Acting so decisively on weight and metabolism therefore makes it possible to target several pathogenic mechanisms simultaneously.

It should, however, be emphasized that remission does not mean permanent cure in every case. Some patients maintain normoglycemia for many years, whereas others experience a gradual recurrence of hyperglycemia, especially if diabetes was long-standing, beta-cell reserve was already markedly reduced, or substantial weight regain occurs. Metabolic surgery is therefore a treatment of great biological potency, but it remains embedded in the natural history of a chronic disease that may evolve over time.

The postoperative period requires active diabetes management because glycemic improvement may be very rapid. Patients who were taking high doses of insulin or multiple drug combinations before surgery may need prompt treatment reduction to prevent hypoglycemia. Regimens cannot be left unchanged. Blood glucose should be monitored closely, insulin requirements reassessed from the first few days, and individual medications reintroduced or discontinued according to the patient’s new metabolic profile.

In patients using sodium-glucose cotransporter 2 inhibitors, correct perioperative discontinuation is essential because fasting, surgical stress, and reduced intake can increase the risk of ketoacidosis. Metformin, basal insulin, and other medications must also be adjusted according to hydration status, kidney function, and resumption of food intake. The immediate postoperative period is therefore not simply a continuation of previous therapy with less food, but a biologically new phase requiring rapid and competent adjustments.

Medium- and long-term follow-up is not limited to monitoring weight. It should document glycated hemoglobin trends, recurrence of hyperglycemia, medication requirements, blood pressure, lipid profile, kidney function, liver health, body composition, and the possible development of nutritional deficiencies. In patients who resume disordered eating or develop food intolerances, dumping, recurrent vomiting, or low protein intake, the risk is not only weight regain but also loss of lean mass and functional deterioration.

Nutritional monitoring must be rigorous. After bypass and procedures with a greater malabsorptive component, iron, ferritin, vitamin B12, folate, vitamin D, calcium, parathyroid hormone, albumin, and, when indicated, other micronutrients should be monitored over time. Vitamin and mineral supplementation is not ancillary, but an integral part of treatment. A patient who has been surgically “treated” from the standpoint of weight may develop anemia, osteopenia, osteoporosis, neuropathy, or protein deficiency if follow-up is abandoned or supplementation is not taken correctly.

Like any major surgery, metabolic surgery entails early perioperative and postoperative complications. The most important include bleeding, leaks or suture-line dehiscence, infections, venous thromboembolism, obstruction, and respiratory complications. The frequency of these events is now relatively low in high-volume centers, but their clinical impact may be considerable. Risk depends on the technique, the center’s experience, the patient’s condition, severe obesity, the presence of obstructive sleep apnea syndrome, heart disease, and other anesthetic factors.

Late complications are often more insidious because they may emerge months or years later and require active surveillance. After gastric bypass, anastomotic strictures, marginal ulcers, internal hernias, early or late dumping, and hyperinsulinemic postprandial hypoglycemia may occur. After sleeve gastrectomy, gastroesophageal reflux, stenosis of the gastric sleeve, or progressive weight regain may develop. More malabsorptive procedures carry a greater risk of diarrhea, protein deficiency, and multiple micronutrient deficiencies.

Nutritional deficiencies are a central issue. Iron, vitamin B12, folate, vitamin D, and calcium are particularly involved, but in more complex cases deficiencies of thiamine, copper, zinc, selenium, or fat-soluble vitamins may occur. The mechanism varies by procedure: reduced intake, bypass of absorptive segments, relative hypochlorhydria, food intolerance, or poor adherence to supplementation. Clinically, this may translate into anemia, neuropathy, fatigue, sarcopenia, bone fragility, and cognitive or neuromuscular disorders.

Another relevant problem is weight regain, which does not necessarily mean failure of the operation but may reduce its metabolic benefit. Causes are multiple: physiologic adaptation, poor dietary adherence, lack of physical activity, psychological problems, dilation of the gastric reservoir in some cases, or selection of a less potent technique in a patient at high risk of recurrence. For this reason as well, metabolic surgery should never be viewed as an isolated act, but as one stage of a chronic therapeutic pathway.

The possibility of achieving remission of type 2 diabetes mellitus is one of the features that makes metabolic surgery so different from most conventional treatments. Remission, however, is not uniform, and its likelihood depends on several predictors. Patients with a shorter duration of disease, better beta-cell reserve, less insulin exposure, relatively younger age, and less severe diabetes at baseline generally have a higher probability of achieving prolonged normoglycemia without medications.

Conversely, when diabetes has been present for many years, insulin requirements are high, and the pancreas has already lost much of its secretory capacity, surgery may still produce major clinical improvement but with a lower likelihood of complete remission. In these cases, benefit more often takes the form of lower glycated hemoglobin, treatment simplification, reduced insulin doses, improvement of comorbidities, and lower overall risk. This point should be communicated clearly, because unrealistic expectations may generate disappointment even in the presence of an excellent clinical result.

A further interpretive limitation concerns the duration of remission. Some patients remain in remission for many years, whereas others experience a gradual rise in blood glucose. This recurrence may depend on weight regain, biological progression of disease, further loss of beta-cell function, or a combination of these factors. Remission should therefore be viewed as a favorable and often highly meaningful metabolic state that must be monitored over time, not as a permanent elimination of diabetes-related risk.

In patients with type 2 diabetes mellitus and obesity, metabolic surgery now occupies a prominent position because it provides a combination of effects rarely matched by other strategies: marked weight loss, robust glycemic improvement, medication reduction, a greater likelihood of remission, and simultaneous benefit across multiple comorbidities. Metabolic prognosis tends to be particularly favorable when surgery is performed while the pancreas still retains a meaningful degree of residual function and when the patient maintains long-term adherence to nutritional recommendations, physical activity, supplementation, and follow-up.

The clinical value of surgery should not, however, be measured solely in terms of remission. Even in patients who do not achieve stable normoglycemia without medications, the possibility of moving from complex treatment regimens to simpler therapies, markedly reducing insulin, and improving hepatic steatosis, obstructive sleep apnea, blood pressure, and quality of life represents an outcome with major prognostic impact. For many patients, metabolic surgery does not completely replace diabetology, but radically enhances its effectiveness.

In conclusion, metabolic surgery is neither the final option after everything else has failed nor an automatic treatment to propose to everyone with obesity and diabetes. It is a major therapy, with precise indications, high biological potency, real risks, and often profound benefits. Its correct clinical place lies at the point of balance between disease severity, likelihood of benefit, the risk profile of the procedure, and the patient’s ability to enter a structured and permanent care pathway.